Neuromedin
B (NMB) receptor antagonist (Ki values are 20.9 and > 10000 nM
for NMB and gastrin-releasing peptide receptors respectively). Selectively
blocks NMB-suppressed glucose intake in vivo. Also a potent urotensin II
receptor antagonist (pA2 = 7.5-7.7) and displays affinity for
somatostatin and μ-opioid receptors.
Ladenheimet al (1994) Blockade of
feeding inhibition by neuromedin B using a selective receptor antagonist.
Eur.J.Pharmacol. 271 R7. Heroldet al (2003) The
neuromedin B receptor antagonist, BIM-23127, is a potent antagonist at human
and rat urotensin-II receptors. Br.J.Pharmacol. 139 203. Santo-Yamadaet al (2003) Blockade of bombesin-like peptide receptors impairs
inhibitory avoidance learning in mice. Neurosci.Lett. 340 65.
“Our laboratory loves dealing with Tocris and consider many of the compounds you sell to be far better quality than the compounds that we have received from other companies. Once again, thank you very much..”
